FDA seeks comment on early-phase solid tumor trial guidance
Tracking: FDA early-phase oncology IND protocol guidanceFDA draft guidance and policy on early-phase investigational new drug protocol recommendations for solid tumors, including comment periods, finalization, and sponsor and patient group advocacy on early-phase cancer trial design.
- Earliest seen
- —
- No coverage yet
- Articles · 30d
- 0
- No coverage
- Outlets
- 0
- —
- Hill · 30d
- 2
- Next: Monday, Jan 11
- Contracts · 30d
- 0
- No awards or solicitations
- Momentum
- 0.0
- Articles ±0 vs prior week
Activity
30 days back, 14 ahead · hollow = scheduledWhat's happening
Updated yesterdayFDA published a draft guidance on Nov. 12 giving sponsors recommendations for early-phase IND protocols for solid tumor drugs and biologics. Public comments are open under docket FDA-2026-D-13432, with a deadline of Jan. 11 or 12, 2027 depending on the source. Finalization would follow the comment period, but no timeline appears in the items.
Hill
3 Hill itemsFDA announced the draft guidance in the Federal Register on Nov. 12; no congressional activity appears in the items.
Contracts
No procurement or funding activity in the window.
Pressure
No outside pressure in the window.
Who covered it, when
A dot per article · ringed = earliest in our sourcesNo coverage in the last 30 days.
Forces at work
share of articles- Regulation3 · 100%FDA issued draft early-phase IND protocol guidance for solid tumors and opened a comment period under docket FDA-2026-D-13432, closing around Jan. 11-12, 2027.FDA
What's next
Times ET11:59 PMAgencyFDAFDA's draft guidance on early-phase IND protocol recommendations for solid tumors is open for public comment through January 12, 2027 under docket FDA-2026-D-13432.Comment deadlineBiotechFDA seeks comment on early-phase solid tumor trial guidanceDetails7 linked
In the news
0 articlesNo coverage yet.
On the Hill
211:59 PMAgencyFDAFDA's draft guidance on early-phase IND protocol recommendations for solid tumors is open for public comment through January 12, 2027 under docket FDA-2026-D-13432.Comment deadlineBiotechFDA seeks comment on early-phase solid tumor trial guidanceDetails7 linked 10d agoAgencyHealth and Human Services DepartmentFDA announced a draft guidance giving sponsors recommendations for early-phase IND protocols for solid tumor drugs and biologics, with comments due January 11, 2027.BiotechFDA seeks comment on early-phase solid tumor trial guidanceDetails14 linked